Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.59 +0.3%	$3.31	$2.70 ▼ $4.72	$688.20M	0.86	712,375 shs	903,453 shs
CRDF Cardiff Oncology	$2.32 +2.7%	$3.24	$2.09 ▼ $5.64	$154.34M	1.54	2.94 million shs	1.02 million shs
KALV KalVista Pharmaceuticals	$13.41 +3.5%	$13.40	$7.30 ▼ $16.32	$669.88M	0.05	796,626 shs	590,122 shs
KURA Kura Oncology	$7.65 +2.8%	$6.26	$5.41 ▼ $21.57	$664M	0.41	1.71 million shs	2.56 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+6.53%	+10.80%	+11.49%	-7.24%
CRDF Cardiff Oncology	0.00%	-4.92%	-43.96%	-23.43%	-0.43%
KALV KalVista Pharmaceuticals	0.00%	+4.11%	-14.04%	+16.91%	+6.60%
KURA Kura Oncology	0.00%	+4.22%	+18.24%	+35.64%	-61.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.7392 of 5 stars	3.5	1.0	0.0	3.5	2.5	0.6
CRDF Cardiff Oncology	1.5834 of 5 stars	3.4	1.0	0.0	0.6	1.7	0.6
KALV KalVista Pharmaceuticals	3.9066 of 5 stars	3.6	1.0	4.4	2.1	1.7	0.6
KURA Kura Oncology	4.0649 of 5 stars	3.4	3.0	4.7	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	53.20% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	335.34% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	96.02% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.10	215.03% Upside

Current Analyst Ratings Breakdown

Latest CRDF, ABUS, KALV, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/11/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$28.00 ➝ $24.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	111.54	N/A	N/A	$0.43 per share	8.35
CRDF Cardiff Oncology	$680K	226.98	N/A	N/A	$0.88 per share	2.64
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
KURA Kura Oncology	$53.88M	12.32	N/A	N/A	$3.52 per share	2.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	11/6/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.26	N/A	N/A	N/A	N/A	-52.32%	-29.59%	11/6/2025 (Estimated)

Latest CRDF, ABUS, KALV, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	-$0.75	-$0.90	-$0.75	$64.95 million	$15.29 million
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
CRDF Cardiff Oncology	N/A	4.42	4.42
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
KURA Kura Oncology	0.02	6.16	6.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CRDF Cardiff Oncology	16.29%
KALV KalVista Pharmaceuticals	N/A
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CRDF Cardiff Oncology	7.70%
KALV KalVista Pharmaceuticals	10.50%
KURA Kura Oncology	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
KURA Kura Oncology	130	86.80 million	81.24 million	Optionable

CRDF, ABUS, KALV, and KURA Headlines

Recent News About These Companies

Alethea Capital Management LLC Raises Holdings in Kura Oncology, Inc. $KURA

August 23 at 7:48 AM | marketbeat.com

Kura Oncology, Inc. $KURA Shares Bought by Algert Global LLC

August 20, 2025 | marketbeat.com

Wall Street Zen Upgrades Kura Oncology (NASDAQ:KURA) to "Hold"

August 18, 2025 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up - Here's Why

August 17, 2025 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up - Still a Buy?

August 17, 2025 | americanbankingnews.com

Kura Oncology Inc. (KURA) Stock Price Today - WSJ

August 16, 2025 | wsj.com

Kura Oncology, Inc. (NASDAQ:KURA) Receives $24.10 Average PT from Analysts

August 15, 2025 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Trading Up 10.7% - What's Next?

August 14, 2025 | marketbeat.com

Kura Oncology (NASDAQ:KURA) Price Target Lowered to $24.00 at JMP Securities

August 14, 2025 | americanbankingnews.com

Kura Oncology’s Earnings Call: Progress Amidst Challenges

August 13, 2025 | msn.com

Kura Oncology (NASDAQ:KURA) Price Target Cut to $24.00 by Analysts at JMP Securities

August 12, 2025 | marketbeat.com

Wedbush Issues Negative Estimate for Kura Oncology Earnings

August 12, 2025 | marketbeat.com

Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 12, 2025 | marketbeat.com

Kura Oncology price target lowered to $27 from $29 at BofA

August 11, 2025 | msn.com

Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates

August 10, 2025 | uk.finance.yahoo.com

Kura Oncology (NASDAQ:KURA) Cut to "Sell" at Wall Street Zen

August 10, 2025 | marketbeat.com

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Kura (KURA) Revenue Drops 61%

August 7, 2025 | fool.com

Kura Oncology Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, ABUS, KALV, and KURA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.59 +0.01 (+0.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.60 +0.01 (+0.14%)

As of 08/22/2025 07:20 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Cardiff Oncology NASDAQ:CRDF

$2.32 +0.06 (+2.65%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.86%)

As of 08/22/2025 07:42 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

KalVista Pharmaceuticals NASDAQ:KALV

$13.41 +0.45 (+3.47%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.41 0.00 (0.00%)

As of 08/22/2025 04:40 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Kura Oncology NASDAQ:KURA

$7.65 +0.21 (+2.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.68 +0.02 (+0.33%)

As of 08/22/2025 07:54 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time